ERX - A thread for everyone

[LATEST NEWS ON ZYC300 - REUTERS 23RD DECEMBER /B]



MGI's second immunotherapy compound in clinical development is ZYC300. ZYC300, an encapsulated plasmid encoding a commonly expressed tumor antigen, has completed a phase I/IIa trial in 17 patients with late-stage metastatic hematological and solid tumors. The enzyme cytochrome P450 1B1 (CYP1B1), is encoded by the ZYC300 plasmid. Reuters sat 23rd dec 2006

EXPECT ANOTHER RNS VERY SOON!!!